REMS
Absorption: 80% absorbed following oral administration.
Distribution: Minimally distributed to tissues.
Half-Life: Immediate release: 21 hr; Extended release: 31 hr.
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | unknown | 2 hr | 12 hr |
PO-ER | unknown | 24 hr | unknown |
‡After single dose.
Contraindicated in:
Use Cautiously in:
Derm: oligohydrosis (↑ in children), STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS
EENT: abnormal vision, diplopia, nystagmus, ↑intraocular pressure, acute myopia/secondary angle closure glaucoma, mydriasis, ocular pain, ocular redness, retinal detachment, visual field defects
Endo: ↓growth (children)
F and E: hyperchloremic metabolic acidosis
GI: nausea, abdominal pain, anorexia, constipation, dry mouth, hyperammonemia
GU: kidney stones
Hemat: BLEEDING, leukopenia
MS: ↓bone mineral density (↑ in children)
Neuro: ataxia, cognitive disorders, dizziness, drowsiness, fatigue, impaired concentration/memory, nervousness, paresthesia, psychomotor slowing, sedation, speech problems, aggressive reaction, agitation, anxiety, confusion, depression, encephalopathy, malaise, mood problems, SEIZURES, SUICIDAL THOUGHTS, tremor
Misc: fever
Drug-drug:
Epilepsy (monotherapy)
Renal Impairment
Epilepsy (adjunctive therapy)
Renal Impairment
Migraine Prevention
Renal Impairment
Lab Test Considerations:
NDC Code